Posted in Multiple Sclerosis Fundraising • Tags: , , at, Awards, Canada, Dinner, Division, Multiple, Multiple_Sclerosis_Fundraising, of, Opal, Pays, Quebec, Quebecers, Sclerosis, Society, The, Three, TO, Tribute
MONTREAL, QUEBEC–(CCNMatthews - March 21, 2006) - The fourth Opal Awards Dinner, named for Evelyn Opal, the founder of the Multiple Sclerosis Society of Canada (MSSC), was held on Wednesday, March 1st, at the Sheraton Centre in Montreal. This prestigious awards ceremony pays tribute to the outstanding achievements and social commitment of three Quebecers. This year’s Opal Awards Dinner raised $451,100 in donations and services for the Multiple Sclerosis Society of Canada, Quebec Division. The money will be used to support research and services for people with multiple sclerosis and their families.
Robert E. Brown, President and CEO of CAE Inc., received the highest distinction of the evening, the Grand Merit Opal Award, for his career achievements and philanthropy.
More →
Share This
Posted on March 22, 2006 by HART (1-800-HART) • There are no comments, hop to it!
Posted in Copaxone, Lipitor • Tags: Combined, Copaxone, Cut, Disease, Dosages, Drug, Effects, Fewer, Half, in, Lipitor, May, Multiple, Negative, or, Reverse, Sclerosis, Side, Stop, with
March 16th 2006
Combining treatments may improve outcomes for patients with Multiple Sclerosis (MS), according to research done on mice and published online by the Journal of Clinical Investigation. Scott S. Zamvil and colleagues at the University of California, San Francisco found that mice treated with a combination of Glatiramer acetate (GA) and atorvastatin (Lipitor) demonstrated “a significant prevention and reversal of clinical MS severity” of MS symptoms.
Lipitor is a cholesterol lowering drug that has previously been shown to improve MS symptoms. Glatiramer acetate (Teva Pharmaceutical Industries Ltd.’s Copaxone) is a drug currently approved for MS treatment. The researchers found that treating MS with combinations of immune modulating drugs can greatly reduce MS disease.
More →
Share This
Posted on March 22, 2006 by HART (1-800-HART) • There are no comments, hop to it!
Posted in Tysabri • Tags: Advisers, Drug, Endorse, FDA, Multiple, of, Return, Sclerosis, Tysabri
03.08.06, 12:00 AM ET
WEDNESDAY, March 8 (HealthDay News) — A U.S. Food and Drug Administration advisory panel voted unanimously Wednesday to allow the promising but controversial multiple sclerosis drug Tysabri back on the market.
The advisers continued to discuss certain controls on who could use the drug, which has been linked to a rare but potentially fatal brain infection. The panel members agreed to a manufacturer plan for a mandatory patient registry; they were scheduled to decide later in the day who would be allowed to enroll in the registry, and how tightly drug use would be limited, the Associated Press reported.
More →
Share This
Posted on March 22, 2006 by HART (1-800-HART) • There are no comments, hop to it!
